Streamlining Gastroenterology Biologics Prior Auth for IBD and Specialty GI

Navigating gastroenterology biologics prior auth is a significant operational challenge for GI practices and health systems. Klivira's platform automates the complex workflows associated with high-cost specialty medications for IBD and other chronic GI conditions.

Revenue cycle directors and prior authorization coordinators in gastroenterology face a high volume of complex prior authorization requests, particularly for biologics. These medications, critical for conditions like Crohn's disease and ulcerative colitis, often involve intricate step therapy protocols, specific documentation, and recurring re-authorization cycles. Manual processes lead to delays, increased administrative burden, and potential revenue loss from denials.

The Unique Burden of GI Biologics Prior Authorization

Gastroenterology prior authorization is heavily concentrated in biologics for inflammatory bowel disease (IBD), advanced imaging, and specific endoscopic procedures. The chronic nature of IBD treatments means ongoing re-authorization cycles, while payer-specific policies for biosimilar substitution and step therapy add layers of complexity. Klivira addresses these unique workflow constraints to optimize PA throughput.

Key PA Triggers in Gastroenterology Biologics

**IBD Biologics:** TNF inhibitors (infliximab, adalimumab, certolizumab, golimumab), integrin inhibitors (vedolizumab), IL-12/23 inhibitors (ustekinumab, risankizumab), JAK inhibitors (tofacitinib, upadacitinib), and S1P modulators (ozanimod, etrasimod).
**Hepatitis C Direct-Acting Antivirals:** Sofosbuvir-velpatasvir, glecaprevir-pibrentasvir, with distinct pathways for treatment-naive vs. experienced patients.
**Advanced Imaging:** MRCP, MR enterography, CT enterography for IBD assessment and other abdominal diagnostics.
**Endoscopic Procedures:** Capsule endoscopy (CPT 91110), small-bowel enteroscopy, ERCP, and EUS for specific indications.
**Specialty Drugs for Functional GI Disorders:** Eluxadoline, prucalopride, linaclotide, and plecanatide.

Critical Documentation and Common Denial Reasons

**IBD Biologics:** Payer policies commonly require diagnosis confirmation, disease severity assessment (Mayo score for UC, CDAI or Harvey-Bradshaw for Crohn's), documented failure of prior conventional therapies (e.g., 5-ASA, immunomodulators), prior biologic experience, and pre-initiation TB/hepatitis screening.
**Step Therapy:** Denials frequently occur due to non-compliance with step therapy, requiring trials of conventional therapy or specific TNF inhibitors before non-TNF agents, or biosimilar substitution.
**Documentation Gaps:** Missing disease severity scores, inadequate screening documentation, or misclassification of treatment status (naive vs. experienced) are common denial drivers.
**Medical Necessity:** For advanced imaging or capsule endoscopy, denials often cite insufficient prior workup or lack of clinical correlation to meet payer-specific medical necessity criteria.

Klivira's Automated Approach to GI Biologics PA

Klivira integrates directly with your EMR to automate the entire gastroenterology biologics prior auth workflow. Our platform leverages ACG and AGA guideline-aware step therapy logic, ensuring compliance with clinical best practices while navigating complex payer requirements. This includes automated identification of prior-line therapies and seamless routing for medical-vs-pharmacy benefit splits.

Klivira Capabilities for Gastroenterology

**Guideline-Aware Step Therapy:** Automates sequencing for IBD biologics based on ACG/AGA guidelines and payer policies.
**Treatment Status Classification:** Automatically identifies treatment-naive vs. treatment-experienced status from EMR medication history for IBD biologics and Hep C DAAs.
**Automated Screening Documentation:** Pulls necessary TB, hepatitis, and immunization status from FHIR data for biologic initiation.
**Periodic Re-authorization:** Manages the typical 6 or 12-month re-authorization cycles for chronic IBD biologics, prompting for continuous disease response documentation.
**Medical-vs-Pharmacy Benefit Routing:** Intelligently routes PA requests based on administration mode (e.g., infusion vs. self-injection) for the same biologic agent.
**Payer-Specific Biosimilar Logic:** Applies per-payer biosimilar substitution mandates, ensuring compliance and reducing denials.

Frequently asked questions

How does Klivira handle the high volume of IBD biologic re-authorizations?

Klivira's platform includes a dedicated workflow for periodic re-authorization of chronic IBD biologics. It proactively tracks authorization expiry dates and triggers the re-authorization process, prompting for necessary updated documentation like disease activity scores to ensure continuous coverage and minimize treatment interruptions.

Can Klivira manage both medical and pharmacy benefit prior authorizations for GI biologics?

Yes, Klivira is designed to manage the complexities of medical-vs-pharmacy benefit splits for biologic agents. It intelligently routes the prior authorization request based on the administration mode (e.g., provider-administered infusion under medical benefit vs. self-administered injection under pharmacy benefit), ensuring the correct channel and documentation are used.

How does Klivira address biosimilar substitution requirements for GI biologics?

Klivira incorporates payer-specific biosimilar substitution policies into its authorization logic. When a brand-name biologic is ordered, the system automatically checks the patient's payer policy for biosimilar mandates and guides the PA coordinator through the appropriate steps, helping to prevent denials related to biosimilar-first requirements.

What EMR data does Klivira use for gastroenterology prior authorizations?

Klivira extracts critical data points from your EMR, including diagnoses, medication history, lab results (e.g., TB/hepatitis screenings, genotype, fibrosis stage), and clinical notes. This data is used to automatically populate PA forms, verify step therapy compliance, and document disease severity assessments like Mayo scores or CDAI.

Does Klivira support specific GI clinical guidelines like ACG or AGA?

Yes, Klivira's step therapy logic and documentation requirements are informed by major clinical guidelines from organizations like the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA). This ensures that prior authorization submissions align with evidence-based medical necessity criteria.